GlycoMark
Healthcare Services · New York, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
805 3rd Ave Fl 17, New York City, New Yo...Phone Number
(212) 355-8165Website
www.glycomark.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
2
1
About GlycoMark
GlycoMark, Inc., based in Manhattan, New York, is dedicated to improving the management and health of patients with diabetes. The company is a joint venture among Toyota Tsusho America, Inc. (New York, NY), Toyota Tsusho Corporation (Tokyo, Japan), and Nippon Kayaku Co., Ltd. (Tokyo, Japan), and is the exclusive supplier of the GlycoMark test in the U.S., Europe, Australia, the Asia-Pacific Region and the Middle East. The GlycoMark test is an FDA cleared non-fasting blood test that detects hyperglycemia and hyperglycemic excursions occurring in the prior 1 to 2 weeks. Since its discovery, the GlycoMark Test, a quantitative test for 1,5-Anhydroglucitol (1,5-AG), has been described in more than 1,300 scientific and medical publications and is shown to be independently associated with complications of diabetes.Explore more
GlycoMark Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is GlycoMark your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at GlycoMark
Earning: See what the market has to say on GlycoMark recently announced quarterly report
Website visits: Recent activity has been detected on your website
Click to see if GlycoMark had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when GlycoMark launches new products
Funding: Get notified immidiatlly once GlycoMark has new funding data
GlycoMark, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if GlycoMark is spiking on competitors!
Check if GlycoMark has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at GlycoMark
Find 3 more new buyers
Company Profile Activity
Activity Insights
GlycoMark is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
GlycoMark is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about GlycoMark.
GlycoMark Tech Stack
A closer look at the technologies used by GlycoMark
GlycoMark News & Media
Additional New GlycoMark® Test and SGLT-2 Inhibitor Clinical Data To Be Presented at the ADA Advancing Precision Diabetes Medicine Symposium
GlycoMark, Inc. announces additional study data describing GlycoMark® test results in patients on SGLT-2 inhibitors are being presented during the American Diabetes Association (ADA) Advancing Precision Diabetes Medicine Research Symposium on October 8 – 9, 2019 in Madrid, Spain. (PRWeb October 07, 2019) Read the full story at https://www.prweb.com/releases/additional_new_glycomark_test_and_sglt_2_inhibitor_clinical_data_to_be_presented_at_the_ada_advancing_precision_diabetes_medicine_symposium/New Clinical Study Data Show the GlycoMark® Test Helps Confirm Compliance and Appropriate Response to SGLT-2 Inhibitors
GlycoMark, Inc. announced a new study “GlycoMark 1,5-Anhydroglucitol Values in Patients Taking SGLT-2 Inhibitors” presented at the American Diabetes Association (ADA) Scientific Sessions 2019 involving the GlycoMark test being used for patients with Type 2 diabetes that are being treated with an SGLT-2 inhibitor. (PRWeb June 13, 2019) Read the full story at https://www.prweb.com/releases/new_clinical_study_data_show_the_glycomark_test_helps_confirm_compliance_and_appropriate_response_to_sglt_2_iNew Data on the GlycoMark® Test In Patients Taking SGLT-2 Inhibitors To Be Presented at the American Diabetes Association 79th Scientific Sessions
GlycoMark, Inc. announces new data on the GlycoMark® test in patients on SGLT-2 inhibitors are being presented June 8 – 10 at the American Diabetes Association (ADA) Scientific Sessions 2019 in San Francisco. (PRWeb June 04, 2019) Read the full story at https://www.prweb.com/releases/new_data_on_the_glycomark_test_in_patients_taking_sglt_2_inhibitors_to_be_presented_at_the_american_diabetes_association_79th_scientific_sessions/prweb16353197.htmLabFinder.com Increases Diabetes Awareness with Addition of the GlycoMark® Test
NEW YORK, Nov. 26, 2018 /PRNewswire/ -- LabFinder.com, a convenient online platform for patients to schedule their laboratory and radiology tests and access test results, has announced the addition of the GlycoMark® test to its growing subscriber network. The GlycoMark® test is an...
Read more news
Top Healthcare Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding GlycoMark
Sign Up For FreeTo access detailed company insights
GlycoMark, Inc., based in Manhattan, New York, is dedicated to improving the management and health of patients with diabetes. The company is a joint venture among Toyota Tsusho America, Inc. (New York, NY), Toyota Tsusho Corporation (Tokyo, Japan), and Nippon Kayaku Co., Ltd. (Tokyo, Japan), and is the exclusive supplier of the GlycoMark test in th... Read More
